Navigation Links
Highlights from BioMarin's Research & Development Day

NOVATO, Calif., Dec. 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today hosted a Research and Development Day where members of the company's management team and industry experts provided an update on BioMarin's product portfolio and advancements in the research and development pipeline.

"We believe 2011 has been a year of significant progress in both our late stage and early stage clinical development programs," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "This progress sets the stage for multiple data readouts in the coming year from key programs throughout our pipeline.  We believe these events will help move us forward in delivering more therapies that could make large impacts on the lives of patients suffering from several rare diseases."

Program Highlights:GALNS for MPS IVA

  • Phase I/II extension data shows continued efficacy
  • Endurance benefits in 6 minute walk test, 3 minute stair climb and pulmonary function tests are sustained
  • Urinary keratan sulfate (uKS) drop is sustained
  • Preliminary growth data encouraging, and biochemical markers suggests that GALNS reaches the cartilages and  improves chondrocyte activity
  • Safety data consistent with earlier results
  • Phase 3 study on track: Enrollment and site quality
  • Risk mitigation strategy implemented
  • BMN-701 for Pompe Disease

  • Good safety profile to date in Phase 1/2 study and cleared to start 20 mg/kg cohort
  • Positive efficacy trends in 5 mg/kg cohort (three patients)
  • Reduced substrate (Urinary tetrasaccharide) in two patients
  • Large improvement in 6 minute walk test in one patient
  • Improved respiratory function in three patients
  • On track to report Phase 1/2 results in 2H 2012
  • PEG-PAL for PKU

  • Successful Type C meeting with FDA
  • Reduction in Phe is an acceptable primary endpoint for Phase III
  • Pivotal trial can be conducted in diet non compliant patients
  • Phase 2 Update
  • Weekly dosing (Part A and B): Good safety profile and substantial Phe reduction achieved in the majority of patients continuing in the study at a median maintenance dose of 1.0 mg/kg/week
  • Daily dosing (Part C): Initial rapid Phe reduction achieved in all patients but not sustained in the majority of patients; joint pain, fever and/or rash reliably ten days after study start
  • Initiating Part D of Phase 2 study to find the quickest and safest induction dosing regimen to an efficacious maintenance dose.  The optimal chronic regimen will be one subcutaneous injection per day.
  • Immunology Update
  • A daily dosing induction schedule leads to higher levels of anti PEG IgM titers and both higher and earlier PAL IgG titers compared to weekly dosing
  • Ways to attenuate the hypersensitivity reactions: Limit dosing when IgM responses are highest and titrate to efficacious doses once the IgG response has developed
  • Some patients do not mount a robust IgM Response to PEG and appear to have sustained efficacy and good tolerance
  • BMN-673 for Genetically-Defined Cancers

  • Dose escalation in Phase 1/2 study in solid tumors continuing after 5 steps (25-400 μg/once per day)
  • PK analysis is ongoing: Preliminary data indicate long terminal half-life
  • Once daily oral dosing is feasible
  • Preliminary results are encouraging in terms of toxicity and signs of efficacy
  • BMN-111 for Achondroplasia

  • Demonstrated benefits in moderately and severely affected animal models
  • Positive therapeutic index predicted in vivo
  • Phase 1 clinical trial in healthy volunteers to begin 1Q 2012
  • Phase 2 proof of concept trial in affected pediatric patients anticipated to begin late 2012/ early 2013
  • Possible development pathway in severely affected infants
  • New Program Introduction: BMN-190 for Late infantile neuronal ceroid lipofuscinosis (LINCL) – Form of Batten DiseaseAt R&D Day, BioMarin also announced a new clinical program, BMN-190 for LINCL, one form of Batten disease.  An orphan neurodegenerative disease, LINCL is caused by buildup of lysosomal storage in the CNS. Tripeptidyl Peptidase-1 (TPP1) enzyme deficiency is due to a mutation in the gene CLN2.  Neurological symptoms present between ages two and four, with patients usually confined to wheelchair and blind by around age six.  Most patients are deceased between the ages eight and twelve. Incidence is estimated at 3.6 to 4.6 per million births and prevalence is between 350 and 1000 patients worldwide, likely higher due to under diagnosis.

    The BMN-190 program is developing a TPP1 enzyme replacement therapy for treatment of LINCL patients.  Pharmacological effects, including functional improvement and life extension, have been robustly demonstrated in relevant animal models of LINCL.  Pharmacokinetic profile (CSF and plasma) and CNS distribution were favorable after ICV infusion.  Toxicity profile is clean after single and repeat ICV infusion administration.

    "The BMN-190 program is a great fit in our growing pipeline.  LINCL patients represent a significant and unmet medical need in an orphan disease," said Hank Fuchs, M.D., Executive Vice President and Chief Medical Officer of BioMarin.  "We believe we can leverage our expertise in biologic manufacturing and proven track record of expeditiously bringing life-altering therapeutics to patients to move this program forward rapidly. We look forward to updating you on advancements in this and other programs in our product pipeline."

    Replay information
    Toll-free number: (855) 859-2056
    International number: (404) 537-3406
    Conference ID #: 28775391

    About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit Information on BioMarin's website is not incorporated by reference into this press release.

    Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme; the financial performance of the BioMarin as a whole; the continued clinical development and commercialization of Naglazyme; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for Naglazyme; actual sales of Naglazyme; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2010 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

    BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

    Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

    Contact: Investors Media Eugenia Shen Bob Purcell BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 506-6570 (415) 506-3267



    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
    3. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
    4. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
    5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
    6. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
    7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
    8. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
    9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
    10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
    11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
    Post Your Comments:
    (Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
    (Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
    (Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take ... an inventor from Austin, Texas, has identified a solution. , She developed a prototype ... restricted lighting. As such, it eliminates the need to turn on a light when ...
    (Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
    (Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
    Breaking Medicine News(10 mins):